Business Context and Reporting Period
This Form 8-K, dated October 22, 2024, reports the completion of a business combination between Ocuphire Pharma, Inc. and Opus Genetics Inc. Following the merger, Ocuphire has been renamed Opus Genetics, Inc., effective October 23, 2024. The company's common stock will trade on the Nasdaq under the new ticker symbol IRD starting October 24, 2024.
Key Financial Metrics
- Cash Position: The pro forma cash balance of the combined company was approximately $37 million as of September 30, 2024 (preliminary and unaudited).
- Liquidity Runway: Management expects a cash runway extending into 2026.
- Equity Issuance: Ocuphire issued 5,237,063 shares of Common Stock and 14,145.374 shares of Series A Non-Voting Convertible Preferred Stock to Opus securityholders.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
- Debt: The filing text does not provide specific debt figures.
Material Changes
- Corporate Structure: Ocuphire acquired Opus Genetics via a two-step merger. Opus became a wholly-owned subsidiary and was subsequently merged into a second merger sub, with Ocuphire (now Opus Genetics) as the surviving entity.
- Capital Structure: Issuance of new Common Stock and Series A Preferred Stock. The Series A Preferred Stock is convertible into 1,000 shares of Common Stock per share and carries cumulative quarterly cash dividends of $26.00 per share commencing October 15, 2025.
- Management Changes:
- Dr. Jay Pepose resigned from the Board.
- Dr. Benjamin R. Yerxa, Dr. Jean Bennett, and Dr. Adrienne Graves were appointed to the Board.
- Dr. Benjamin R. Yerxa was appointed President of the combined company.
- Stockholder Restrictions: Certain securityholders are subject to 180-day lock-up agreements regarding the sale or transfer of shares.
Guidance, Outlook, and Risks
Outlook: The company anticipates a cash runway into 2026 based on the $37 million pro forma cash balance. The merger is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Management Commentary: The transaction is designed to integrate Opus Genetics' gene therapy platform with Ocuphire's existing capabilities. Dr. Yerxa brings significant experience in ophthalmology and retinal degenerative diseases.
Risks and Contingencies:
- Regulatory and Clinical Risks: Success depends on regulatory submissions, clinical trial enrollment, and data readouts.
- Capital Requirements: Risks related to the inability to obtain sufficient additional capital to advance product candidates.
- Integration Risks: Ability to realize expected benefits from the acquisition and execute clinical programs for gene therapies.
- Market Risks: Substantial competition, rapid technological change, and fluctuations in stock price.
- Legal and Operational: Potential product liability, securities litigation, and reliance on third parties.
Investor Verification Checklist
- Verify the pro forma cash balance of $37 million and the projected runway into 2026 in the investor presentation (Exhibit 99.2).
- Review the terms of the Series A Preferred Stock, specifically the $26.00 quarterly dividend obligation starting October 2025.
- Confirm the 180-day lock-up period restrictions on shares held by Opus securityholders and Ocuphire directors/officers.
- Monitor the upcoming Stockholders' Meeting for approval of the conversion of Series A Preferred Stock into Common Stock.
- Check for the filing of pro forma financial information, which is expected to be filed by amendment within 71 days of this report.